63615-91-8

Basic information

• Product Name: 2-Thiazolamine, N-(3-chlorophenyl)-
• CAS NO: 63615-91-8
• Molecular Formula: C9H7ClN2S
• Molecular Weight: 210.687
• Mol File: 63615-91-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-Thiazolamine, N-(3-chlorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiazolamine, N-(3-chlorophenyl)-(63615-91-8)
• EPA Substance Registry System: 2-Thiazolamine, N-(3-chlorophenyl)-(63615-91-8)

Safety Data

• Hazardous Substances Data: 63615-91-8(Hazardous Substances Data)

Upstream product

• 4947-89-1 1-(3-chlorophenyl)-2-thiourea 
• 75-07-0 acetaldehyde 
• 2392-68-9 3-chlorophenyl-isothiocyanate 
• 107-20-0 2-chloroethanal 

Downstream Products

• 63615-96-3 5-bromo-N-(3-chlorophenyl)thiazol-2-amine 
• 63616-03-5 (3-chloro-phenyl)-((3ar,7ac)-3a,5,6,7a-tetrahydro-[1,4]dioxino[2,3-d]thiazol-2-yl)-amine 
• 63616-03-5 (3-chloro-phenyl)-((3ar,7at)-3a,5,6,7a-tetrahydro-[1,4]dioxino[2,3-d]thiazol-2-yl)-amine 

Relevant articles and documents

NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS

This invention relates to novel compounds which are inhibitors of acyl coenzyme A: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (Type 1, Type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia- related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as mycocardial, renal and liver fibrosis, hepatitis C virus infection and acne or other skin disorders.